Congrats - I remember when I first did it, weight off my shoulders!
10.03.2026 19:07
👍 1
🔁 0
💬 0
📌 0
Congrats - I remember when I first did it, weight off my shoulders!
Category H now live on OpenPrescribing
Example med openprescribing.net/tariff/?code...
#pharmsky
OpenSAFELY is open from today! Huge thanks to all who supported this vast collaboration: whole population GP data; in a productive platform; innovative privacy protections; unprecedented support from professions, privacy campaigners; &c
Now it's over to users!
www.bennett.ox.ac.uk/blog/2026/02...
Figure
New BMJ Research: Time trends in newly recorded diagnoses of 19 long term conditions before, during, and after the covid-19 pandemic: population based cohort study in England
www.bmj.com/content/392/...
🚨 OpenSAFELY Milestone Paper!
How did the pandemic affect diagnosis rates for chronic diseases?
We analysed rates for 19 long-term conditions in 30m people in England. The results are out this week in @bmj.com
📄 Read here: doi.org/10.1136/bmj-...
Huge team effort supported by NHSE. Special hat tip 2 Mark Russell @kingscollegelondon.bsky.social who led this project and to all across the OpenSAFELY project!
A starter pack for your perusal - if those are still a thing?!
bsky.app/starter-pack...
And read the paper!
www.bmj.com/content/392/...
The real benefit is that we now have NHS data infrastircture through OpenSAFELY that means we can re run the analysis whenever is needed
"We must no longer accept waiting years to understand disease burden"
As it says in this excellent linked editorial
www.bmj.com/content/392/...
There is important information about health inequalities. Briefly for example e.g. subgroup analyses, diagnosis rates for dementia have increased
above preC19 levels for people of white ethnicity and those from less deprived areas, but not for those from other ethnicities or more deprived areas
This information is really important for continued planning of NHS services.
The @bmj.com have used our data to make even more beautiful charts than we made!
Check them out public.flourish.studio/visualisatio...
Five years on, the recovery varies :
📊 Depression diagnoses are nearly 30% lower than expected (dropping since 2022). 🩸 In contrast, Chronic Kidney Disease (CKD) diagnoses have risen by ~35% above expected levels.
www.bmj.com/content/392/...
Note this is not completely new information. See our earlier OpenSAFELY work in @bjgp.bsky.social
doi.org/10.3399/BJGP...
doi.org/10.3399/BJGP...
And @elife.bsky.social !
elifesciences.org/articles/84673
📉 What did we find?
Diagnosis rates fell sharply for all 19 conditions during the early pandemic.
For example lung diseases (asthma, COPD) and skin conditions (psoriasis, atopic dermatitis) were affected early on.
The scale is phenomenal.
Using anonymised data for 30 million people via the NHS England OpenSAFELY service, we tracked conditions ranging from Asthma & COPD to Heart Failure & Depression & and many more
🚨 OpenSAFELY Milestone Paper!
How did the pandemic affect diagnosis rates for chronic diseases?
We analysed rates for 19 long-term conditions in 30m people in England. The results are out this week in @bmj.com
📄 Read here: doi.org/10.1136/bmj-...
In this study, Rose Higgins and colleagues look at opioid prescribing in patients on orthopaedic waiting lists during the pandemic to understand the impact of longer elective wait times.
https://bmjmedicine.bmj.com/content/4/1/e001743
OpenSAFELY 💪
Disease surveillance capacity is very useful, particularly when integrated with decision making by design. We should build even more. www.bmj.com/content/392/...
lol
On a train - lost reliable internet!
Thread another time. Read the paper
www.bmj.com/content/392/...
And the linked editorial
www.bmj.com/content/392/...
⏰New OpenSAFELY paper alert ⏰
Time trends in newly recorded diagnoses of 19 long term conditions before, during, and after the covid-19 pandemic: population based cohort study in England using OpenSAFELY
www.bmj.com/content/392/...
Out today in @bmj.com led by an expert team at Kings!
#medsky 🧵
So good I listened twice ;)
My weekend listening sorted!
New paper from our team out over Christmas in BJCP
Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in England
pubmed.ncbi.nlm.nih.gov/41406988/
Sometimes research becomes more relevant after you’ve written it 🧵
#medsky #haematology
Remember this is not just a paper that lives on a dusty shelf
Now over to you 👇
Go and check what andexanet alfa use looks like in your hospital on OpenPrescribing.
hospitals.openprescribing.net
It hasn’t been withdrawn in the UK, and there may still be appropriate use cases.
🙏 Massive thanks to the co-authors and collaborators who made this possible.
This kind of transparency and rapid, reproducible analysis is essential if we’re serious about evidence-based and equitable care.
All operating in near real time - available on hospital wards throughout England for live ward round audits!
hospitals.openprescribing.net
This is the first published study using OpenPrescribing Hospitals to analyse adoption of a new hospital medicine.
A LIVE living machine for studying variation, value, and policy impact across the NHS - that is accessible 24/7
hospitals.openprescribing.net
But this paper isn’t really about andexanet alfa.
It’s much bigger than that!
What we saw was striking:
• Large variation between trusts
• Clear regional differences
• Very different speeds of adoption
Back to what we did!
We used OpenPrescribing Hospitals data to examine how andexanet alfa has been taken up across NHS trusts in England since its NICE recommendation in 2021.
Please do see full methods if interested!
pubmed.ncbi.nlm.nih.gov/41406988/